Context is everything: aneuploidy in cancer
Publication type: Journal Article
Publication date: 2019-09-23
scimago Q1
wos Q1
SJR: 16.364
CiteScore: 57.7
Impact factor: 52.0
ISSN: 14710056, 14710064
PubMed ID:
31548659
Molecular Biology
Genetics
Genetics (clinical)
Abstract
Cancer is driven by multiple types of genetic alterations, which range in size from point mutations to whole-chromosome gains and losses, known as aneuploidy. Chromosome instability, the process that gives rise to aneuploidy, can promote tumorigenesis by increasing genetic heterogeneity and promoting tumour evolution. However, much less is known about how aneuploidy itself contributes to tumour formation and progression. Unlike some pan-cancer oncogenes and tumour suppressor genes that drive transformation in virtually all cell types and cellular contexts, aneuploidy is not a universal promoter of tumorigenesis. Instead, recent studies suggest that aneuploidy is a context-dependent, cancer-type-specific oncogenic event that may have clinical relevance as a prognostic marker and as a potential therapeutic target. Aneuploidy contributes to tumorigenesis, but the underlying processes are not well understood. This Review explains the context dependency of aneuploidy in cancer and discusses its clinical potential as a prognostic marker and a therapeutic target.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
12
14
16
18
|
|
|
Nature Communications
17 publications, 2.92%
|
|
|
bioRxiv
15 publications, 2.58%
|
|
|
Cancers
14 publications, 2.41%
|
|
|
International Journal of Molecular Sciences
14 publications, 2.41%
|
|
|
Nature
12 publications, 2.06%
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
10 publications, 1.72%
|
|
|
Frontiers in Oncology
9 publications, 1.55%
|
|
|
Cell Reports
9 publications, 1.55%
|
|
|
eLife
9 publications, 1.55%
|
|
|
Chromosome Research
8 publications, 1.37%
|
|
|
Scientific Reports
8 publications, 1.37%
|
|
|
Journal of Cell Biology
7 publications, 1.2%
|
|
|
Genes
6 publications, 1.03%
|
|
|
Cells
6 publications, 1.03%
|
|
|
Current Biology
6 publications, 1.03%
|
|
|
Frontiers in Cell and Developmental Biology
5 publications, 0.86%
|
|
|
Frontiers in Genetics
5 publications, 0.86%
|
|
|
Nature Reviews Genetics
5 publications, 0.86%
|
|
|
EMBO Journal
5 publications, 0.86%
|
|
|
Frontiers in Immunology
4 publications, 0.69%
|
|
|
Genome Biology
4 publications, 0.69%
|
|
|
Nature Cell Biology
4 publications, 0.69%
|
|
|
Communications Biology
4 publications, 0.69%
|
|
|
Cell
4 publications, 0.69%
|
|
|
Cancer Discovery
4 publications, 0.69%
|
|
|
EMBO Reports
4 publications, 0.69%
|
|
|
Cancer Research
4 publications, 0.69%
|
|
|
Clinical Cancer Research
4 publications, 0.69%
|
|
|
Molecular Cell
4 publications, 0.69%
|
|
|
2
4
6
8
10
12
14
16
18
|
Publishers
|
20
40
60
80
100
120
140
|
|
|
Springer Nature
123 publications, 21.13%
|
|
|
Cold Spring Harbor Laboratory
120 publications, 20.62%
|
|
|
Elsevier
92 publications, 15.81%
|
|
|
MDPI
50 publications, 8.59%
|
|
|
Wiley
32 publications, 5.5%
|
|
|
Frontiers Media S.A.
29 publications, 4.98%
|
|
|
Oxford University Press
18 publications, 3.09%
|
|
|
American Association for Cancer Research (AACR)
13 publications, 2.23%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
10 publications, 1.72%
|
|
|
Public Library of Science (PLoS)
9 publications, 1.55%
|
|
|
eLife Sciences Publications
9 publications, 1.55%
|
|
|
Rockefeller University Press
7 publications, 1.2%
|
|
|
European Molecular Biology Organization
7 publications, 1.2%
|
|
|
Taylor & Francis
6 publications, 1.03%
|
|
|
American Association for the Advancement of Science (AAAS)
4 publications, 0.69%
|
|
|
Annual Reviews
4 publications, 0.69%
|
|
|
The Company of Biologists
3 publications, 0.52%
|
|
|
American Society for Cell Biology (ASCB)
3 publications, 0.52%
|
|
|
F1000 Research
2 publications, 0.34%
|
|
|
Spandidos Publications
2 publications, 0.34%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 0.34%
|
|
|
Impact Journals
2 publications, 0.34%
|
|
|
AME Publishing Company
2 publications, 0.34%
|
|
|
IMR Press
2 publications, 0.34%
|
|
|
Microbiology Society
1 publication, 0.17%
|
|
|
The Royal Society
1 publication, 0.17%
|
|
|
Neoplasia Press
1 publication, 0.17%
|
|
|
SAGE
1 publication, 0.17%
|
|
|
Federation of American Societies for Experimental Biology (FASEB)
1 publication, 0.17%
|
|
|
20
40
60
80
100
120
140
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
582
Total citations:
582
Citations from 2024:
216
(37.11%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Ben-David U. et al. Context is everything: aneuploidy in cancer // Nature Reviews Genetics. 2019. Vol. 21. No. 1. pp. 44-62.
GOST all authors (up to 50)
Copy
Ben-David U., Amon A. Context is everything: aneuploidy in cancer // Nature Reviews Genetics. 2019. Vol. 21. No. 1. pp. 44-62.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1038/s41576-019-0171-x
UR - https://www.nature.com/articles/s41576-019-0171-x
TI - Context is everything: aneuploidy in cancer
T2 - Nature Reviews Genetics
AU - Ben-David, Uri
AU - Amon, Angelika
PY - 2019
DA - 2019/09/23
PB - Springer Nature
SP - 44-62
IS - 1
VL - 21
PMID - 31548659
SN - 1471-0056
SN - 1471-0064
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2019_Ben-David,
author = {Uri Ben-David and Angelika Amon},
title = {Context is everything: aneuploidy in cancer},
journal = {Nature Reviews Genetics},
year = {2019},
volume = {21},
publisher = {Springer Nature},
month = {sep},
url = {https://www.nature.com/articles/s41576-019-0171-x},
number = {1},
pages = {44--62},
doi = {10.1038/s41576-019-0171-x}
}
Cite this
MLA
Copy
Ben-David, Uri, et al. “Context is everything: aneuploidy in cancer.” Nature Reviews Genetics, vol. 21, no. 1, Sep. 2019, pp. 44-62. https://www.nature.com/articles/s41576-019-0171-x.